PE20091432A1 - Composicion farmaceutica - Google Patents
Composicion farmaceuticaInfo
- Publication number
- PE20091432A1 PE20091432A1 PE2009000307A PE2009000307A PE20091432A1 PE 20091432 A1 PE20091432 A1 PE 20091432A1 PE 2009000307 A PE2009000307 A PE 2009000307A PE 2009000307 A PE2009000307 A PE 2009000307A PE 20091432 A1 PE20091432 A1 PE 20091432A1
- Authority
- PE
- Peru
- Prior art keywords
- halo
- absent
- pharmaceutical composition
- cyclodextrin
- tio
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/716—Glucans
- A61K31/724—Cyclodextrins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
- A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Molecular Biology (AREA)
- Dermatology (AREA)
- Nanotechnology (AREA)
- Diabetes (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Biotechnology (AREA)
- Psychology (AREA)
- Hematology (AREA)
- Crystallography & Structural Chemistry (AREA)
- Medical Informatics (AREA)
- General Engineering & Computer Science (AREA)
- Immunology (AREA)
- Biophysics (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Heart & Thoracic Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Pulmonology (AREA)
- Communicable Diseases (AREA)
- Obesity (AREA)
- Rheumatology (AREA)
Abstract
SE REFIERE A UNA COMPOSICION FARMACEUTICA QUE CONTIENE: A) UN COMPUESTO DE FORMULA (I) DONDE Z, Z1, Z2, Z3, Z4 Y Z5 SON CADA UNO C O N; R1 ESTA AUSENTE O ES Y1-R12; R2 ESTA AUSENTE O ES Y2-R13, EN DONDE Y1, Y2 E Y3 SON CADA UNO UN CONECTOR O ESTAN AUSENTES; R12 Y R13 SON CADA UNO H, HALO, NITRO, CN, TIO, ENTRE OTROS; R4 ES H, HALO, CN, OXI, ENTRE OTROS; R5 Y R6 SON CADA UNO H, CN, TIO, HIDROXI, ENTRE OTROS; R7 ES H, HALO, AMINO, ENTRE OTROS; R14 ES H, AMINO, SULFONILO, ENTRE OTROS, EN DONDE UN COMPUESTO PREFERIDO ES 5-(3-(ETILSULFONIL)FENIL)-3,8-DIMETIL-N-(1-METILPIPERIDIN-4-IL)-9H-PIRIDO[2,3-b]INDOL-7-CARBOXAMIDA; B) UN DERIVADO DE CICLODEXTRINA TAL COMO LA SAL DE SODIO DE SULFOBUTIL ETER- -CICLODEXTRINA EN UNA CANTIDAD DE 0,01% A 90% P/V; Y C) AGUA. DICHA COMPOSICION ES UTIL EN EL TRATAMIENTO DE CANCER, PSORIASIS, SINDROME DE DOWN, ENFERMEDAD DE PARKINSON
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US3216508P | 2008-02-28 | 2008-02-28 |
Publications (1)
Publication Number | Publication Date |
---|---|
PE20091432A1 true PE20091432A1 (es) | 2009-10-17 |
Family
ID=40560232
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PE2009000307A PE20091432A1 (es) | 2008-02-28 | 2009-02-27 | Composicion farmaceutica |
Country Status (22)
Country | Link |
---|---|
US (1) | US20100331357A1 (es) |
EP (1) | EP2252291A1 (es) |
JP (1) | JP2011513201A (es) |
KR (1) | KR20100129308A (es) |
CN (1) | CN102014901A (es) |
AR (1) | AR071354A1 (es) |
AU (1) | AU2009217969A1 (es) |
BR (1) | BRPI0908077A2 (es) |
CA (1) | CA2716720A1 (es) |
CL (1) | CL2009000453A1 (es) |
CO (1) | CO6290659A2 (es) |
CR (1) | CR11660A (es) |
DO (1) | DOP2010000262A (es) |
EA (1) | EA201071007A1 (es) |
EC (1) | ECSP10010505A (es) |
IL (1) | IL207734A0 (es) |
MA (1) | MA32165B1 (es) |
MX (1) | MX2010009513A (es) |
PE (1) | PE20091432A1 (es) |
TW (1) | TW200938544A (es) |
WO (1) | WO2009107877A1 (es) |
ZA (1) | ZA201006224B (es) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102827307B (zh) * | 2011-06-17 | 2015-06-17 | 首都医科大学 | β-环糊精修饰的四氢-β-咔啉羧酸衍生物及其制备方法和应用 |
CN103450371A (zh) * | 2012-06-01 | 2013-12-18 | 首都医科大学 | 四氢-β-咔啉-3-甲酰基-二乙烯三胺-β-环糊精,其制备,抗血栓活性和应用 |
AR091727A1 (es) * | 2012-07-12 | 2015-02-25 | Sanofi Sa | Composicion anti-tumoral que comprende el compuesto 1-(6-{[6-(4-fluorofenil)[1,2,4]triazolo[4,3-b]piridazin-3-il]sulfanil}-1,3-benzotiazol-2-il)-3-(2-morfolin-4-iletil)urea |
US9474756B2 (en) * | 2014-08-08 | 2016-10-25 | Forsight Vision4, Inc. | Stable and soluble formulations of receptor tyrosine kinase inhibitors, and methods of preparation thereof |
JP2017155023A (ja) * | 2016-03-04 | 2017-09-07 | ジェイファーマ株式会社 | Lat1阻害活性を有する芳香族アミノ酸誘導体を含有する注射剤 |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE3346123A1 (de) * | 1983-12-21 | 1985-06-27 | Janssen Pharmaceutica, N.V., Beerse | Pharmazeutische praeparate von in wasser schwerloeslichen oder instabilen arzneistoffen und verfahren zu ihrer herstellung |
KR0166088B1 (ko) * | 1990-01-23 | 1999-01-15 | . | 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도 |
EP1903039A4 (en) * | 2005-06-13 | 2010-09-22 | Takeda Pharmaceutical | INJECTION |
US8119655B2 (en) * | 2005-10-07 | 2012-02-21 | Takeda Pharmaceutical Company Limited | Kinase inhibitors |
-
2009
- 2009-02-27 AU AU2009217969A patent/AU2009217969A1/en not_active Abandoned
- 2009-02-27 TW TW098106336A patent/TW200938544A/zh unknown
- 2009-02-27 AR ARP090100683A patent/AR071354A1/es unknown
- 2009-02-27 EA EA201071007A patent/EA201071007A1/ru unknown
- 2009-02-27 CL CL2009000453A patent/CL2009000453A1/es unknown
- 2009-02-27 BR BRPI0908077-5A patent/BRPI0908077A2/pt not_active IP Right Cessation
- 2009-02-27 EP EP09715407A patent/EP2252291A1/en not_active Withdrawn
- 2009-02-27 MX MX2010009513A patent/MX2010009513A/es not_active Application Discontinuation
- 2009-02-27 PE PE2009000307A patent/PE20091432A1/es not_active Application Discontinuation
- 2009-02-27 CA CA2716720A patent/CA2716720A1/en not_active Abandoned
- 2009-02-27 CN CN2009801151237A patent/CN102014901A/zh active Pending
- 2009-02-27 JP JP2010534172A patent/JP2011513201A/ja not_active Withdrawn
- 2009-02-27 KR KR1020107021500A patent/KR20100129308A/ko not_active Application Discontinuation
- 2009-02-27 WO PCT/JP2009/054237 patent/WO2009107877A1/en active Application Filing
- 2009-02-27 US US12/918,505 patent/US20100331357A1/en not_active Abandoned
-
2010
- 2010-08-22 IL IL207734A patent/IL207734A0/en unknown
- 2010-08-27 DO DO2010000262A patent/DOP2010000262A/es unknown
- 2010-08-31 ZA ZA2010/06224A patent/ZA201006224B/en unknown
- 2010-08-31 CR CR11660A patent/CR11660A/es not_active Application Discontinuation
- 2010-09-21 MA MA33196A patent/MA32165B1/fr unknown
- 2010-09-27 EC EC2010010505A patent/ECSP10010505A/es unknown
- 2010-09-28 CO CO10119568A patent/CO6290659A2/es not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
CL2009000453A1 (es) | 2010-08-13 |
MA32165B1 (fr) | 2011-03-01 |
US20100331357A1 (en) | 2010-12-30 |
WO2009107877A1 (en) | 2009-09-03 |
BRPI0908077A2 (pt) | 2015-08-25 |
EP2252291A1 (en) | 2010-11-24 |
CR11660A (es) | 2010-11-25 |
CA2716720A1 (en) | 2009-09-03 |
DOP2010000262A (es) | 2010-09-30 |
MX2010009513A (es) | 2010-09-22 |
JP2011513201A (ja) | 2011-04-28 |
ECSP10010505A (es) | 2010-10-30 |
CO6290659A2 (es) | 2011-06-20 |
ZA201006224B (en) | 2011-11-30 |
AR071354A1 (es) | 2010-06-16 |
EA201071007A1 (ru) | 2011-04-29 |
TW200938544A (en) | 2009-09-16 |
AU2009217969A1 (en) | 2009-09-03 |
KR20100129308A (ko) | 2010-12-08 |
IL207734A0 (en) | 2010-12-30 |
CN102014901A (zh) | 2011-04-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PE20110568A1 (es) | Agentes terapeuticos 414 | |
EA200971107A1 (ru) | Катехоламиновые производные, полезные для лечения болезни паркинсона | |
CR10383A (es) | Derivados triazolopirazina. | |
CY1111170T1 (el) | Ενωσεις διαρυλ αιθερα ουριας | |
ATE482210T1 (de) | Oxadiazolderivate als s1p1-rezeptor-agonisten | |
FR2903107B1 (fr) | Derives d'imidazopyridine-2-carboxamides, leur preparation et leur application en therapeutique | |
CL2007002705A1 (es) | Composicion farmaceutica oftalmica autopreservada que comprende 0,04 a 0,9 mm de iones zinc donde la concentracion de aniones tamponantes es menor que 15 mm. | |
TN2009000199A1 (en) | Heteromonocyclic compound and use thereof | |
BRPI0500704A (pt) | composições de tratamento pessoal reidratáveis | |
MX2011012627A (es) | Derivados aminobutiricos sustituidos como inhibidores de nepralisina. | |
NO20075111L (no) | Farmasoytisk sammensetning | |
MY157715A (en) | Cytotoxic agents comprising new tomaymycin derivatives and their therapeutic use | |
PE20071061A1 (es) | Derivados de carbonilo como inhibidores de peptidil-deformilasa (pdf) | |
PE20091432A1 (es) | Composicion farmaceutica | |
EA201070164A1 (ru) | Твердый препарат, включающий алоглиптин и гидрохлорид метформина | |
DK2074120T3 (da) | Tropan-forbindelser | |
EA200701251A1 (ru) | Цитотоксические агенты, содержащие новые таксаны | |
PE20081596A1 (es) | Derivados fluorinados de deferiprona | |
TW200639159A (en) | Treatment of pain | |
MY155658A (en) | A-isopropylphenyl glucitol compounds as sglti inhibitors | |
EA201200968A1 (ru) | Применение транс-кломифена для предотвращения или лечения диабета 2 типа у мужчин | |
PE20090363A1 (es) | Moduladores de la gamma secretasa | |
NO20076219L (no) | Farmasoytisk formulering med apomorfin for bukkal administrering | |
BRPI0418181A (pt) | emprego de 2-aminotetralinas substituìdas para prevenção do tratamento de morbus parkinson | |
JP2012512863A5 (es) |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FD | Application declared void or lapsed |